AU2017270092B2 - Compositions and methods for treating pulmonary vascular disease - Google Patents

Compositions and methods for treating pulmonary vascular disease Download PDF

Info

Publication number
AU2017270092B2
AU2017270092B2 AU2017270092A AU2017270092A AU2017270092B2 AU 2017270092 B2 AU2017270092 B2 AU 2017270092B2 AU 2017270092 A AU2017270092 A AU 2017270092A AU 2017270092 A AU2017270092 A AU 2017270092A AU 2017270092 B2 AU2017270092 B2 AU 2017270092B2
Authority
AU
Australia
Prior art keywords
pro
leu
ser
gly
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017270092A
Other languages
English (en)
Other versions
AU2017270092A1 (en
Inventor
Thomas BERTERO
Stephen Y. CHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
University of Pittsburgh
Original Assignee
Brigham and Womens Hospital Inc
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, University of Pittsburgh filed Critical Brigham and Womens Hospital Inc
Publication of AU2017270092A1 publication Critical patent/AU2017270092A1/en
Application granted granted Critical
Publication of AU2017270092B2 publication Critical patent/AU2017270092B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2017270092A 2016-05-26 2017-05-25 Compositions and methods for treating pulmonary vascular disease Active AU2017270092B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341848P 2016-05-26 2016-05-26
US62/341,848 2016-05-26
PCT/US2017/034420 WO2017205595A1 (en) 2016-05-26 2017-05-25 Compositions and methods for treating pulmonary vascular disease

Publications (2)

Publication Number Publication Date
AU2017270092A1 AU2017270092A1 (en) 2018-12-06
AU2017270092B2 true AU2017270092B2 (en) 2022-04-14

Family

ID=60412630

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017270092A Active AU2017270092B2 (en) 2016-05-26 2017-05-25 Compositions and methods for treating pulmonary vascular disease

Country Status (7)

Country Link
US (2) US10925869B2 (enExample)
EP (2) EP3463574B1 (enExample)
JP (2) JP7079937B2 (enExample)
KR (2) KR102434879B1 (enExample)
CN (2) CN115192719B (enExample)
AU (1) AU2017270092B2 (enExample)
WO (1) WO2017205595A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115192719B (zh) 2016-05-26 2024-03-01 匹兹堡大学联邦高等教育系统 用于治疗肺血管疾病的组合物和方法
EP3713569B1 (en) * 2017-11-22 2024-03-13 University of Pittsburgh- Of the Commonwealth System of Higher Education Therapeutic particle comprising a yap1/wwrt1 inhibiting agent and the glutaminase inhibiting agent 2-cyclopropyl-n-[5-(4-{ [5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]amino}piperidin-1-yl)-1,3,4-thiadiazol-2-yl] acetamide and use thereof for treating a pulmonary disease
JP7156856B2 (ja) * 2018-08-21 2022-10-19 国立大学法人富山大学 抗肥満剤
EP3690108B1 (en) 2019-02-01 2021-05-12 LG Electronics Inc. Laundry treating apparatus
EP3690109B1 (en) 2019-02-01 2021-05-05 LG Electronics Inc. Laundry treating apparatus
EP3690110B1 (en) 2019-02-01 2021-06-02 LG Electronics Inc. Laundry treating apparatus
WO2020226919A1 (en) * 2019-05-05 2020-11-12 Georgetown University Use of inhibitors of yap/taz for the treatment of cancer
EP3980072A4 (en) * 2019-06-05 2023-06-14 University of Georgia Research Foundation COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED PULMONARY HYPERTENSION
JP7514508B2 (ja) * 2020-05-19 2024-07-11 国立大学法人鳥取大学 胆道がん治療薬
US20240082158A1 (en) * 2020-05-21 2024-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
CN116421591A (zh) * 2023-05-10 2023-07-14 哈尔滨医科大学大庆分校 Ldha抑制剂在制备治疗肺动脉高压的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5798345A (en) 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5707608A (en) 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
WO2009102707A2 (en) * 2008-02-11 2009-08-20 Auspex Pharmaceuticals, Inc. Substituted oxazaphosphorines
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
KR100963435B1 (ko) 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20170226507A1 (en) * 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
US20160058759A1 (en) 2014-07-03 2016-03-03 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
WO2016019368A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) * 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
AU2016219161A1 (en) 2015-02-12 2017-08-31 The Johns Hopkins University Inhibition of Yap for breaking tumor immune tolerance
US20180311353A1 (en) 2015-07-02 2018-11-01 Children's Medical Center Corporation Triplet-triplet annihilation-based upconversion
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
CN115192719B (zh) * 2016-05-26 2024-03-01 匹兹堡大学联邦高等教育系统 用于治疗肺血管疾病的组合物和方法
EP3713569B1 (en) * 2017-11-22 2024-03-13 University of Pittsburgh- Of the Commonwealth System of Higher Education Therapeutic particle comprising a yap1/wwrt1 inhibiting agent and the glutaminase inhibiting agent 2-cyclopropyl-n-[5-(4-{ [5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]amino}piperidin-1-yl)-1,3,4-thiadiazol-2-yl] acetamide and use thereof for treating a pulmonary disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kimura, T. E. et al., "The Hippo Pathway Mediates Inhibition of Vascular Smooth Muscle Cell Proliferation by cAMP", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2015, vol. 90, pages 1-10, DOI: 10.1016/j.yjmcc.2015.11.024 *
Kudryashova, T. V. et al., "HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension", AM J RESP CRIT CARE MED, vol. 194, no. 7, 27 April 2016, pp. 866-877 *
Piersma, B. et al., "Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge", FRONTIERS IN MEDICINE, 2015, vol. 2, article 59, DOI: 10.3389/fmed.2015.00059 *

Also Published As

Publication number Publication date
CN115192719A (zh) 2022-10-18
JP7411967B2 (ja) 2024-01-12
KR20190013926A (ko) 2019-02-11
JP7079937B2 (ja) 2022-06-03
AU2017270092A1 (en) 2018-12-06
CN109843378A (zh) 2019-06-04
US10925869B2 (en) 2021-02-23
CA3025401A1 (en) 2017-11-30
EP3463574A4 (en) 2020-07-29
WO2017205595A1 (en) 2017-11-30
US11672795B2 (en) 2023-06-13
EP3463574B1 (en) 2021-11-03
CN115192719B (zh) 2024-03-01
KR102434879B1 (ko) 2022-08-22
US20190298710A1 (en) 2019-10-03
EP3970720A1 (en) 2022-03-23
EP3463574A1 (en) 2019-04-10
JP2019519533A (ja) 2019-07-11
KR20220120711A (ko) 2022-08-30
CN109843378B (zh) 2022-06-10
EP3970720B1 (en) 2023-07-05
US20210154187A1 (en) 2021-05-27
JP2022119825A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
US11672795B2 (en) Compositions and methods for treating pulmonary vascular disease
Yang et al. The ER-localized Ca2+-binding protein calreticulin couples ER stress to autophagy by associating with microtubule-associated protein 1A/1B light chain 3
US11331290B2 (en) Niclosamide for the treatment of cancer metastasis
Koshman et al. Regulation of connective tissue growth factor gene expression and fibrosis in human heart failure
Rosin et al. Disruption of collagen homeostasis can reverse established age-related myocardial fibrosis
RU2736499C1 (ru) Специфические ингибиторы гексокиназы-2 для применения при остром повреждении центральной нервной системы
CN107106580A (zh) 治疗癌症干细胞的组合物
AU2017281980B2 (en) Wnt inhibitors for use in the treatment of fibrosis
Huang et al. Crosstalk between PML and p53 in response to TGF-β1: A new mechanism of cardiac fibroblast activation
CA3025401C (en) Compositions and methods for treating pulmonary vascular disease
AU2022203624A1 (en) Compositions and methods for treating pulmonary vascular disease
WO2021151079A1 (en) Modulating lymphatic vessels in neurological disease
Zhang et al. YBX1-driven TUBB6 upregulation facilitates ocular angiogenesis via WNT3A-FZD8 pathway
HK40006997B (en) Compositions and methods for treating pulmonary vascular disease
US20160199445A1 (en) Use of arpin a new inhibitor of the arp2/3 complex for the diagnosis and treatment of diseases
WO2021015218A1 (ja) 転写関連因子を標的とする線維化疾患の予防または治療
Liu et al. TLR9-HIF-1α-VEGF axis is essential for HMGB1-mediate post-myocardial infarction tissue repair
US20160362686A1 (en) Composition including rcc1-regulating substance for reducing senescence of cell or subject and method of reducing senescence of cell or subject by using the composition
CN118451095A (zh) 间皮ecm移动的调节剂
Hogan-Cann Proteolytic Cleavage of the Kv1. 5 Channel in the S1-S2 Linker Does Not Affect Channel Function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)